株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

前立腺がん診断の世界市場:タイプ(予備検査、確認検査)別 市場分析と予測 2018年~2025年

Prostate Cancer Diagnostics Market Analysis Report By Type (Preliminary Tests, Confirmatory Tests), By Region (North America, APAC, Europe, MEA, Latin America), And Segment Forecasts, 2018 - 2025

発行 Grand View Research, Inc. 商品コード 726439
出版日 ページ情報 英文 75 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=109.21円で換算しております。
Back to Top
前立腺がん診断の世界市場:タイプ(予備検査、確認検査)別 市場分析と予測 2018年~2025年 Prostate Cancer Diagnostics Market Analysis Report By Type (Preliminary Tests, Confirmatory Tests), By Region (North America, APAC, Europe, MEA, Latin America), And Segment Forecasts, 2018 - 2025
出版日: 2018年08月16日 ページ情報: 英文 75 Pages
概要

世界の前立腺がん診断市場は、2018年から2025年にかけて12.3%のCAGRで推移し、2025年までに55億米ドル規模の市場に成長することが予測されています。前立腺がんの有病率の上昇、継続的な技術進歩などによって当市場の成長が促進されています。

当レポートでは、世界の前立腺がん診断市場を調査し、市場の概要、タイプ・地域別の市場規模の推移と予測、市場動向、市場の成長要因および阻害要因の分析、市場機会、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 調査方法

  • 情報調達
  • データ分析

第2章 エグゼクティブサマリー

  • 市場のスナップショット

第3章 市場変数、市場動向、範囲

  • 市場区分と範囲
  • 普及と成長見通しマッピング
  • SWOT分析(政治、法、経済、技術の観点から)
  • ファイブフォース分析

第4章 前立腺がん診断市場の分析:タイプ別

  • 市場動向の分析:タイプ別
  • 予備検査
  • 確認検査
    • PCA3検査
    • 経直腸的超音波検査
    • 生検

第5章 前立腺がん診断市場の分析:地域別

  • 市場動向の分析:地域別
  • 市場シェア:地域別(実績値・予測値)
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第6章 競合情勢

  • 戦略の枠組み
  • 企業プロファイル
    • MDxHealth
    • 3D Signatures
    • Genomic Health
    • Abbott
    • OPKO Health, Inc.
    • Siemens Healthcare GmbH
    • DiaSorin S.p.A.
    • bioMerieux SA
    • F. Hoffman La Roche Ltd.
    • Beckman Coulter, Inc.
    • Myriad Genetic, Inc.
図表

List of Tables

  • TABLE 1 North America Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
  • TABLE 2 U.S. Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
  • TABLE 3 Canada Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
  • TABLE 4 Europe Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
  • TABLE 5 Germany Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
  • TABLE 6 U.K. Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
  • TABLE 7 Asia-Pacific Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
  • TABLE 8 Japan Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
  • TABLE 9 China Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
  • TABLE 10 Latin America Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
  • TABLE 11 Brazil Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
  • TABLE 12 Mexico Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
  • TABLE 13 Middle East & Africa Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
  • TABLE 14 South Africa Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information Procurement
  • FIG. 3 Primary research pattern
  • FIG. 4 Market research approaches
  • FIG. 5 Value chain based sizing & forecasting
  • FIG. 6 QFD modelling for market share assessment
  • FIG. 7 Market summary (USD Million), 2015
  • FIG. 8 Market trends & outlook
  • FIG. 9 Market segmentation & scope
  • FIG. 10 Market driver relevance analysis (Current & future impact)
  • FIG. 11 Market restraint relevance analysis (Current & future impact)
  • FIG. 12 Penetration & growth prospect mapping
  • FIG. 13 SWOT Analysis, By Factor (political & legal, economic and technological)
  • FIG. 14 Porter's Five Forces Analysis
  • FIG. 15 Prostate Cancer Diagnostics market: Type outlook key takeaways
  • FIG. 16 Prostate Cancer Diagnostics: Type Movement Analysis, USD Million
  • FIG. 17 Preliminary Tests Market, 2014 - 2025 (USD Million)
  • FIG. 18 Confirmatory Tests Market, 2014 - 2025 (USD Million)
  • FIG. 19 PCA3Test Market, 2014 - 2025 (USD Million)
  • FIG. 20 Trans-rectal ultrasound Market, 2014 - 2025 (USD Million)
  • FIG. 21 Biopsy Market, 2014 - 2025 (USD Million)
  • FIG. 22 Regional market place: Key takeaways
  • FIG. 23 Prostate Cancer Diagnostics Market: Regional Movement Analysis, USD Million
  • FIG. 24 North America market, 2014 - 2025 (USD Million)
  • FIG. 25 U.S. market, 2014 - 2025 (USD Million)
  • FIG. 26 Canada market, 2014 - 2025 (USD Million)
  • FIG. 27 Europe market, 2014 - 2025 (USD Million)
  • FIG. 28 U.K. market, 2014 - 2025 (USD Million)
  • FIG. 29 Germany market, 2014 - 2025 (USD Million)
  • FIG. 30 Asia Pacific market, 2014 - 2025 (USD Million)
  • FIG. 31 Japan market, 2014 - 2025 (USD Million)
  • FIG. 32 China market, 2014 - 2025 (USD Million)
  • FIG. 33 Latin America market, 2014 - 2025 (USD Million)
  • FIG. 34 Brazil market, 2014 - 2025 (USD Million)
  • FIG. 35 Mexico market, 2014 - 2025 (USD Million)
  • FIG. 36 MEA market, 2014 - 2025 (USD Million)
  • FIG. 37 South Africa market, 2014 - 2025 (USD Million)
  • FIG. 38 Strategy framework
目次
Product Code: GVR-2-68038-548-9

The global prostate cancer diagnostics market size is expected to reach USD 5.5 billion by 2025, according to a new report by Grand View Research, Inc. The market is estimated to expand at a CAGR of 12.3% during the forecast years. Demand for prostate cancer diagnostics is increasing owing to rising prevalence of the disease along with constant technological advancements and awareness regarding the same.

Every year, more than 2,30,000 men are diagnosed with prostate cancer. In addition, as per a study conducted by the American Cancer Society, prostate cancer is the third leading cause of cancer-related deaths in U .S. Constant development of new technologies for the disease diagnosis and treatment would drive the market over the coming years.

Magnetic Resonance Imaging (MRI) technology and Fusion biopsy are the new technologies used for the disease diagnosis. Fusion biopsy is a technique, which uses the combination of MRI and ultrasound. Some of the leading companies in the prostate cancer diagnostics market are MDx Health; Abbott Laboratories; Siemens Healthcare GmbH; F. Hoffman-La Roche AG; Myriad Genetics, Inc.; Genomic Health; and OPKO Health, Inc.

Further key findings from the study suggest:

  • Increasing prevalence of prostate cancer is primarily boosting the market growth across the globe
  • Growing awareness regarding the disease and available treatments along with supportive government initiatives would also drive the market
  • The preliminary tests segment captured the largest market share of prostate cancer diagnostics in 2016
  • Confirmatory tests segment is said to expand at the fastest CAGR due to low risk of infection, convenience, and non-invasive nature of these tests
  • North America is dominant regional market followed by Europe due to sophisticated healthcare infrastructure and availability of technologically advanced products

Key companies in the market include: MDx Health; Abbott Laboratories; Siemens Healthcare GmbH; F. Hoffman-La Roche AG; Myriad Genetics, Inc.; Genomic Health; and OPKO Health, Inc.

Table of Contents

Chapter 1 Research Methodology

  • 1.1 Information procurement
  • 1.2 Information or Data Analysis
    • 1.2.1 Market Formulation & Validation
  • 1.3 Region Wise Market Calculation
    • 1.3.1 Region Wise Market: Base Estimates
    • 1.3.2 Global Market: CAGR Calculation

Chapter 2 Executive Summary

  • 2.1 Market Snapshot

Chapter 3 Prostate Cancer Diagnostics Market Variables, Trends & Scope

  • 3.1 Market segmentation & scope
    • 3.1.1 Market Driver Analysis
      • 3.1.1.1 Increasing prevalence of prostate cancer
      • 3.1.1.2 Increasing government initiatives
      • 3.1.1.3 Technological advancements
    • 3.1.2 Market Restraint Analysis
      • 3.1.2.1 High cost of diagnosis
  • 3.2 Penetration & growth prospect mapping
  • 3.3 Prostate Cancer Diagnostics - SWOT Analysis, By Factor (political & legal, economic and technological)
  • 3.4 Industry Analysis - Porter's

Chapter 4 Prostate Cancer Diagnostics Market: Type Estimates & Trend Analysis

  • 4.1 Prostate cancer diagnostics market: Type movement analysis
  • 4.2 Preliminary Tests
  • 4.3 Confirmatory Tests
    • 4.3.1. Confirmatory Tests Market Estimates & Segment Forecast, 2014 - 2025 (USD Million)
    • 4.3.2 PCA3Test
      • 4.3.2.1 PCA3Test Market, 2014 - 2025 (USD Million)
    • 4.3.3 Trans-rectal ultrasound
      • 4.3.3.1 Trans-rectal ultrasound Market, 2014 - 2025 (USD Million)
    • 4.3.4 Biopsy
      • 4.3.4.1 Biopsy Market, 2014 - 2025 (USD Million)

Chapter 5 Prostate Cancer Diagnostics Market: Regional Estimates & Trend Analysis, by Type

  • 5.1 Prostate Cancer Diagnostics Market: Regional Movement Analysis
  • 5.2 Prostate cancer diagnostics market share by region, 2015 & 2025
  • 5.3 North America
    • 5.3.1 North America market, 2014 - 2025 (USD Million)
    • 5.3.2 U.S.
      • 5.3.2.1 U.S. market, 2014 - 2025 (USD Million)
    • 5.3.3 Canada
      • 5.3.3.1 Canada market, 2014 - 2025 (USD Million)
  • 5.4 Europe
    • 5.4.1 Europe market, 2014 - 2025 (USD Million)
    • 5.4.2 U.K.
      • 5.4.2.1 U.K. market, 2014 - 2025 (USD Million)
    • 5.4.3 Germany
      • 5.4.3.1 Germany market, 2014-2025 (USD Million)
  • 5.5 Asia Pacific
    • 5.5.1 Asia Pacific market, 2014 - 2025 (USD Million)
    • 5.5.2 Japan
      • 5.5.2.1 Japan market, 2014 - 2025 (USD Million)
    • 5.5.3 China
      • 5.5.3.1 China market, 2014 - 2025 (USD Million)
  • 5.6 Latin America
    • 5.6.1 Latin America market, 2014 - 2025 (USD Million)
    • 5.6.2 Brazil
      • 5.6.2.1 Brazil market, 2014 - 2025 (USD Million)
    • 5.6.3 Mexico
      • 5.6.3.1 Mexico market, 2014 - 2025 (USD Million)
  • 5.7 MEA
    • 5.7.1 MEA market, 2014 - 2025 (USD Million)
    • 5.7.2 South Africa
      • 5.7.2.1 South Africa market, 2014 - 2025 (USD Million)

Chapter 6 Competitive Landscape

  • 6.1 Strategy framework
  • 6.2 Company Profiles
    • 6.2.1 MDxHealth
      • 6.2.1.1 Company overview
      • 6.2.1.2 Financial performance
      • 6.2.1.3 Product benchmarking
      • 6.2.1.4 Strategic initiatives
    • 6.2.2 3D Signatures
      • 6.2.2.1 Company overview
      • 6.2.2.2 Product benchmarking
      • 6.2.2.3 Strategic initiatives
    • 6.2.3 Genomic Health
      • 6.2.3.1 Company overview
      • 6.2.3.2 Financial Performance
      • 6.2.3.3 Product Benchmarking
      • 6.2.3.4 Strategic initiatives
    • 6.2.4 Abbott
      • 6.2.4.1 Company overview
      • 6.2.4.2 Financial performance
      • 6.2.4.3 Product benchmarking
    • 6.2.5 OPKO Health, Inc.
      • 6.2.5.1 Company overview
      • 6.2.5.2 Financial performance
      • 6.2.5.3 Product benchmarking
    • 6.2.6 Siemens Healthcare GmbH
      • 6.2.6.1 Company overview
      • 6.2.6.2 Financial Performance
      • 6.2.6.3 Product benchmarking
    • 6.2.7 DiaSorin S.p.A.
      • 6.2.7.1 Company overview
      • 6.2.7.2 Financial performance
      • 6.2.7.3 Product benchmarking
      • 6.2.7.4 Strategic initiatives
    • 6.2.8 bioMerieux SA
      • 6.2.8.1 Company overview
      • 6.2.8.2 Financial performance
      • 6.2.8.3 Product benchmarking
    • 6.2.9 F. Hoffman La Roche Ltd.
      • 6.2.9.1 Company overview
      • 6.2.9.2 Financial performance
      • 6.2.9.3 Product benchmarking
      • 6.2.9.4 Strategic initiatives
    • 6.2.10 Beckman Coulter, Inc.
      • 6.2.10.1 Company overview
      • 6.2.10.2 Financial performance
      • 6.2.10.3 Product benchmarking
    • 6.2.11 Myriad Genetic, Inc.
      • 6.2.11.1 Company overview
      • 6.2.11.2 Financial performance
      • 6.2.11.3 Product benchmarking
      • 6.2.11.4 Strategic Initiatives
Back to Top